AU Patent

AU2023202671A1 — Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor

Assigned to Pharmacyclics LLC · Expires 2023-05-18 · 3y expired

What this patent protects

PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract FIG.1 0- FormulationA 25 - --- FormulationB - ---- Formulation C ------ Formulation D CL 2 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyr…

USPTO Abstract

PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract FIG.1 0- FormulationA 25 - --- FormulationB - ---- Formulation C ------ Formulation D CL 2 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor -((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo [3,4-d]pyrimidin 1-yl)piperidin-1-yl)prop-2-en--one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023202671A1
Jurisdiction
AU
Classification
—
Expires
2023-05-18
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.